naltrexone
Adjunctive therapy • Brands: Revia, Depade
Last reviewed: 2026-02-12
General information
- Class: Adjunctive therapy
- Common US brands: Revia, Depade
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2026-02-12
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Opioid receptor antagonist used for alcohol dependence and for opioid dependence relapse prevention via opioid blockade; requires an opioid-free period to avoid precipitated withdrawal and has hepatotoxicity cautions at higher doses.
Metabolism & Half‑life
- Metabolism: Extensive hepatic metabolism (first pass)
- Half‑life: Single-dose mean 4 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- Naltrexone hydrochloride tablets prescribing information — DailyMed (2026)
- Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis — JAMA (2014)
- AGNP TDM Consensus — Pharmacopsychiatry (2018)
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management — Journal of Addiction Medicine (2020)